CytoGenix Inc. Commences Animal Trials for Its Anti-Herpes DNA Formulation.

Business Editors/Health/Medical Writers

HOUSTON--(BUSINESS WIRE)--July 28, 2003

CytoGenix Inc. (OTCBB:CYGX) announced today that the first phase of its animal trials of its anti-herpes topical cream has begun. The study is comprised of 120 mice in eight groups. Mice are excellent herpes disease models because they die within a few weeks after infection if left untreated. Preliminary results are expected within 30 days.

"These trials will demonstrate safety and pharmacologic effectiveness prior to human studies. In addition, we are testing our formulation for use as a prophylactic (preventative) as well as a therapeutic for long term cure," states Dr. Malcolm Skolnick, CytoGenix' president/CEO. "Existing herpes treatments do not meet the needs of the millions of sufferers of this debilitating and highly infectious disease. Follow-on studies in human subjects should prove the formulation's safety and effectiveness as a long-term treatment," adds Dr. Skolnick.

Herpes is a serious public health problem. The U.S. Centers for Disease Control has classified genital herpes as an epidemic and reports that "genital herpes -- herpes simplex virus type two (HSV-2)-- is one of the most common sexually transmitted diseases in the United States, with as many as one million people becoming infected each year. While genital herpes continues to spread across all social, economic, racial and ethnic boundaries, prevalence of infection increased most dramatically in teens and young adults. The disease is potentially fatal in newborns and can be particularly severe in people with HIV infection. HSV-2 infection is more common in women (approximately one out of four women) than in men (almost one out of five)."

CytoGenix Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development, including anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a U.S. patent for its core DNA expression technology and has 40 international or U.S. pending patent applications.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com.